| The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project A Wimo, L Jönsson, A Gustavsson, D McDaid, K Ersek, J Georges, ... International journal of geriatric psychiatry 26 (8), 825-832, 2011 | 307 | 2011 |
| Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky British journal of dermatology 175 (3), 561-571, 2016 | 227 | 2016 |
| The changing landscape of biosimilars in rheumatology T Dörner, V Strand, P Cornes, J Gonçalves, L Gulácsi, J Kay, TK Kvien, ... Annals of the rheumatic diseases 75 (6), 974-982, 2016 | 222 | 2016 |
| Statement of the European Pressure Ulcer Advisory Panel—pressure ulcer classification: differentiation between pressure ulcers and moisture lesions T Defloor, L Schoonhoven, J Fletcher, K Furtado, H Heyman, M Lubbers, ... Journal of Wound Ostomy & Continence Nursing 32 (5), 302-306, 2005 | 199 | 2005 |
| The state of the art in European research on reducing social exclusion and stigma related to mental health: a systematic mapping of the literature S Evans-Lacko, E Courtin, A Fiorillo, M Knapp, M Luciano, AL Park, ... European Psychiatry 29 (6), 381-389, 2014 | 173 | 2014 |
| EQ-5D in central and Eastern Europe: 2000–2015 F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ... Quality of Life Research 25, 2693-2710, 2016 | 139 | 2016 |
| Biosimilars for the management of rheumatoid arthritis: economic considerations L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek Expert review of clinical immunology 11 (sup1), 43-52, 2015 | 121 | 2015 |
| The implementation of quality management systems in hospitals: a comparison between three countries C Wagner, L Gulácsi, E Takacs, M Outinen BMC health services research 6, 1-11, 2006 | 117 | 2006 |
| Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003 M Pentek, C Horváth, I Boncz, Z Falusi, E Tóth, A Sebestyen, I Májer, ... Osteoporosis international 19, 243-249, 2008 | 116 | 2008 |
| Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria L Gulácsi, AM Rotar, M Niewada, O Löblová, F Rencz, G Petrova, I Boncz, ... The European journal of health economics 15, 13-25, 2014 | 113 | 2014 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ... The European Journal of Health Economics 15, 111-119, 2014 | 95 | 2014 |
| Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response D Kringos, F Carinci, E Barbazza, V Bos, K Gilmore, O Groene, L Gulácsi, ... Health research policy and systems 18, 1-8, 2020 | 93 | 2020 |
| A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016 | 90 | 2016 |
| Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A Śliwczyński, ... World Journal of Gastroenterology: WJG 21 (6), 1728, 2015 | 85 | 2015 |
| Adherence to biologic DMARD therapies in rheumatoid arthritis T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi Expert opinion on biological therapy 10 (9), 1367-1378, 2010 | 84 | 2010 |
| Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics MD Michael, A Bálint, BD Lovász, L Gulácsi, B Strbák, PA Golovics, ... The European Journal of Health Economics 15, 121-128, 2014 | 83 | 2014 |
| The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek Advances in therapy 34, 1128-1144, 2017 | 80 | 2017 |
| Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 79 | 2020 |
| Cost-of-illness of patients with systemic sclerosis in a tertiary care centre T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgar, L Czirjak, ... Rheumatology 49 (10), 1920-1928, 2010 | 77 | 2010 |
| Budget-impact analyses: a critical review of published studies E Orlewska, L Gulácsi Pharmacoeconomics 27, 807-827, 2009 | 76 | 2009 |
Márta PéntekÓbudai Egyetem在 uni-obuda.hu 的电子邮件经过验证
